Clinical Trial Search

Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants

Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08

Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants

Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants

Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects

Primary: Incidence of Acute GVHD — 45.0 percentage of participants

Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants

Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients

Primary: Number of Participants With Complete Response (CR) — 34 Participants

Primary: GVHD-free Survival — 60; 69; 59; 47 participants

Primary: Grades II-IV aGVHD — 11 Participants

Primary: Estimated Percentage of Participants With Event Free Survival — 45; 54 percentage of participants

Primary: Cummalative Incidence of Grade 2 to 4 Acute Graft vs Host Diesease (GVHD) at Day 100 Post Transplant in HSCT Recipients — 3.3 percentage of participants — p=<0.05

Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63

Primary: The Maximum Tolerated Dose and Toxicity Profile of an 8 Week Course of IL-2 in Patients With cGVHD and an Inadequate Response to Steroids. — 1 million IU/m2/day

Primary: Chronic Graft-vs-Host Disease (cGvHD) — 20 percentage of participants

Primary: Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by…

Primary: The Number of Patients With Relapse-free/Donor Lymphocyte Infusion(DLI)-Free Survival Rates Between Patients Randomized to MMF-30 (Control Cohort) and MMF-15…

Primary: Number of Participants With Grades II-IV Acute GVHD — 44; 34; 32 Participants — p=0.09

Primary: Rate of Dose Limiting Toxicities — 0.045 proportion of participants of DLT

Primary: Percentage of Participants With Evidence of Acute Graft Versus Host Disease (aGVHD), Post Transplant — 43; 89 percentage of participants

Primary: 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) — 22 percentage of participants

Primary: Composite Success Rate — 100; 75; 84 Percentage of participants

Primary: Percentage of Participants With Grades II to IV aGVHD at Day +100 of Atorvastatin Administration — 30 percentage of patients

Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants

Primary: Percentage of Participants With Complete or Partial Response (CR/PR) to Acute GVHD Treatment — 35; 46; 19; 17 Participants

Primary: T Regulatory Cell (Treg)/Total Cluster of Differentiation 4 (CD4)+ Ratio — 13; 11 ratio

Primary: Safety and Tolerability of Belimumab as Prophylaxis of Chronic GvHD in Subjects Following alloHCT as Measured by Number of Participants Who Experience Each Adverse Event…

Primary: Graft-versus-host Disease Free Relapse Free (GRFS) at 1 Year — 56 percentage of probability

Primary: Number of Patients Absence of Grade II-IV aGVHD or Chronic GVHD Diagnostic Features — 13; 5 Participants